Osalmid

Osalmid is a small molecule choleretic drug primarily used to stimulate bile production and secretion in the liver, acting directly on hepatocytes. It has been approved for the treatment of cholestasis and is sometimes used in combination with antibiotics during the convalescent stage of infectious hepatitis. Mechanistically, Osalmid acts as a potent inhibitor of Ribonucleotide reductase small subunit M2 (RRM2), showing greater activity than hydroxyurea in inhibiting ribonucleotide reductase activity. This inhibition leads to reduced DNA synthesis and has demonstrated antiviral effects against hepatitis B virus (HBV), as well as antitumor activities including chemosensitization and enhancement of radiotherapy efficacy in cancers such as esophageal cancer and multiple myeloma[1][5][6][7]. Osalmid also affects autophagy pathways by inhibiting autophagosome–lysosome fusion through modulation of RRM2-RIPK3 interactions[5].

Brand names

bilenedribazilsalmidocholauxobilenidrandrioldriol-labazbilocol

Other names

2-hydroxy-n-(4-hydroxyphenyl)benzamide4'-hydroxysalicylanilidesaryuurinoksafenamidosalmidap'-hydroxysalicylanilideoxaphenamidumhydroxyphenyl salicylamidep-hydroxyphenylsalicylamiden'-salicyloyl-p‑aminophenolbenzamide, 2-hydroxy-n-(4-hydroxyphenyl)-n-(p‑hydroxyphenyl)salicylamiden-(4‑hydroxyphenyl)salicylamideosalmidum